Author

R. Harvey

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6 Microbiology· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 11 Research Focus:host-pathogen & immune response· 8 Organism:human· 7 Assay:proteomics· 5 Research Focus:drug response / drug discovery· 3 Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2

Frequent Co-Authors

S. Hussain· 8 shared C. Swanton· 6 shared J. Mccauley· 6 shared S. Gandhi· 6 shared G. Kassiotis· 5 shared S. Gamblin· 5 shared M. Howell· 4 shared N. Faulkner· 4 shared

Activity by Year

2020-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersImmunology

S. Hussain

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1

G. Dowgier, A. Hobbs, D. Greenwood, M. Shawe-Taylor, P. Stevenson-Leggett, J. Bazire, R. Penn, R. Harvey, V. Libri, G. Kassiotis, S. Gamblin, N. S. Lewis, B. Williams, C. Swanton, S. Gandhi, , M. Y. Wu

The paper evaluates neutralising antibody titres against SARS-CoV-2 variant JN.1 using live-virus microneutralisation assays in vaccinated individuals, finding higher titres in monovalent vaccine recipients.

bioRxiv · Apr 17, 2024 · PreprintMicrobiology

Dichotomy of neutralizing antibody, B cell and T cell responses to SARS-CoV-2 vaccination and protection in healthy adults

E. J. Carr, H. Townsley, M. Y. Wu, K. A. Wilkinson, P. S. Hobson, D. Levi, S. Namjou, H. V. Mears, A. Hobbs, M. Ragno, L. S. Herman, R. Harvey, C. Bailey, A. S. Fowler, E. Hatipoglu, , E. C. Wall

The paper identifies four patterns of SARS-CoV-2 vaccine responses, including broad and narrow responders, and links broad responder traits to longer infection-free time after vaccination.

bioRxiv · May 24, 2023 · PreprintImmunology

Emergence of new subgenomic mRNAs in SARS-CoV-2

H. V. Mears, G. R. Young, T. Sanderson, R. Harvey, M. Crawford, D. M. Snell, A. S. Fowler, S. Hussain, J. Nicod, T. P. Peacock, E. Emmott, K. Finsterbusch, J. Luptak, E. Wall, B. Williams, , D. L. Bauer

This study identifies new subgenomic mRNAs in SARS-CoV-2 arising from mutations that create novel transcription regulatory sequences, leading to the expression of functional proteins like N.iORF3.

bioRxiv · Apr 20, 2022 · PreprintMicrobiology

SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export

R. Hall, A. Guedan, M. W. Yap, G. R. Young, R. Harvey, J. P. Stoye, K. N. Bishop

This paper shows that SARS-CoV-2 ORF6 inhibits mRNA export by interacting with Rae1, suppressing antiviral responses and aiding viral replication.

bioRxiv · Feb 8, 2022Microbiology

Broad human and animal coronavirus neutralisation by SARS-CoV-2 S2-targeted vaccination

K. Ng, N. Faulkner, K. Finsterbusch, M. Wu, R. Harvey, S. Hussain, M. Greco, Y. Liu, S. Kjaer, C. Swanton, S. Gandhi, R. Beale, S. Gamblin, P. Cherepanov, J. Mccauley, , G. Kassiotis

This study shows that SARS-CoV-2 S2-targeted vaccination induces broad neutralizing antibodies against multiple coronaviruses and provides better protection than homologous boosting.

bioRxiv · Nov 30, 2021 · PreprintImmunology

Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp13 Helicase

R. Beale, A. P. Bertolin, A. Borg, B. Canal, J. F. Diffley, L. S. Drury, R. Harvey, M. Howell, S. Hussain, S. Kjaer, J. McCauley, L. McCoy, J. Milligan, V. Posse, C. Roustan, , J. Zeng

This study identifies small molecule inhibitors of SARS-CoV-2 nsp13 helicase by screening a chemical library and validates their antiviral efficacy in cell culture.

bioRxiv · Apr 7, 2021Biochemistry

Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains

N. Faulkner, K. Ng, M. Wu, R. Harvey, S. Hussain, M. Greco, W. Bolland, S. Warchal, M. Margaritis, S. Paraskevopoulou, J. Heaney, H. Rickman, C. Houlihan, M. Spyer, D. Frampton, , G. Kassiotis

This study compares antibody cross-reactivity between SARS-CoV-2 B.1.1.7 and parental strains, finding reduced recognition and neutralization of older variants after B.1.1.7 infection.

bioRxiv · Mar 1, 2021Immunology

Favourable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases

C. Deakin, G. Cornish, K. Ng, N. Faulkner, W. Bolland, V. Panova, J. Hope, A. Rosa, R. Harvey, S. Hussain, C. Earl, B. Jebson, M. Wilkinson, L. Marshall, K. O'Brien, , G. Kassiotis

The paper examines antibody responses to HCoV-OC43 and SARS-CoV-2 in children with autoimmune rheumatic diseases, finding stronger spike antibody responses and cross-reactivity despite immunosuppressive treatment.

bioRxiv · Feb 15, 2021 · PreprintImmunology

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

T. K. Tan, P. Rijal, R. Rahikainen, A. Keeble, L. Schimanski, S. Hussain, R. Harvey, J. Hayes, J. Edwards, R. McLean, V. Martini, M. Pedrera, N. Thakur, C. Conceicao, I. Dietrich, , R. Owens

This study develops a vaccine candidate using SpyCatcher technology to display the SARS-CoV-2 RBD, showing strong neutralizing antibody responses in mice and pigs.

bioRxiv · Aug 31, 2020Immunology

Plasmablast-derived antibody response to acute SARS-CoV-2 infection in humans

K.-Y. A. Huang, T. Tan, T.-H. Chen, C.-G. Huang, R. Harvey, S. Hussain, C.-P. Chen, A. Harding, J. Gilbert-Jaramillo, X. Liu, M. Knight, L. Schimanski, S.-R. Shih, Y.-C. Lin, C.-Y. Cheng, , A. Townsend

This study analyzes plasmablast-derived antibodies in three COVID-19 patients, identifying neutralizing antibodies and cross-reactivity with other betacoronaviruses.

bioRxiv · Aug 28, 2020 · PreprintMicrobiology

Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans

K. W. Ng, N. Faulkner, G. Cornish, A. Rosa, R. Harvey, S. Hussain, R. Ulferts, C. Earl, A. Wrobel, D. Benton, C. Roustan, W. Bolland, R. Thompson, A. Agua-Doce, P. Hobson, , Mc

The paper identifies pre-existing and de novo humoral immunity to SARS-CoV-2 in humans, showing that uninfected individuals have SARS-CoV-2 S-reactive antibodies, particularly in children, and that infection leads to higher antibody titres targeting multiple subunits.

bioRxiv · May 14, 2020Immunology